Product Description
Mechanisms of Action: APM1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Chroma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Myelodysplastic Syndrome|Leukemia|Acute Myeloid Leukemia
Phase 2: Non-Small-Cell Lung Cancer|Acute Myeloid Leukemia|Adenocarcinoma|Preleukemia|Pancreatic Cancer|Myelodysplastic Syndrome|Anemia, Refractory, with Excess of Blasts|Multiple Myeloma|Leukemia, Plasma Cell|Leukemia
Phase 1: Oncology Solid Tumor Unspecified|Acute Myeloid Leukemia|Healthy Volunteers|Preleukemia|Myelodysplastic Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2006-7041-83/hah | N/A |
Not yet recruiting |
Surgical Wound Infection |
2020-05-04 |
|||
| 2006-7041-83/hah | N/A |
Not yet recruiting |
Pain Unspecified|Healthy Volunteers |
None |
|||
| NCI-2018-01817 | P1 |
Terminated |
Acute Myeloid Leukemia|Myelodysplastic Syndrome|Preleukemia |
2019-07-04 |
2020-04-14 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
|
| 8265134 | P1 |
Completed |
Healthy Volunteers |
2012-07-01 |
2023-09-19 |
Primary Endpoints|Treatments|Trial Status |
|
| CHR-2797-003 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2008-03-01 |
2019-03-18 |
Treatments |
|
| CHR-2797-001 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2007-11-01 |
2019-03-18 |
Treatments |
|
| MUK three | P2 |
Completed |
Multiple Myeloma |
2017-10-30 |
2022-03-13 |
Treatments |
|
| IST-CTI-MDS | P2 |
Completed |
Myelodysplastic Syndrome|Preleukemia |
2017-10-25 |
2019-03-20 |
Treatments |
|
| NCT02352831 | P2 |
Terminated |
Pancreatic Cancer|Adenocarcinoma |
2017-10-20 |
2019-03-20 |
Treatments |
|
| 2012-000334-19 | P2 |
Active, not recruiting |
Acute Myeloid Leukemia |
2015-04-17 |
2022-03-13 |
Treatments |
|
| NCI-2012-00274 | P2 |
Completed |
Preleukemia|Myelodysplastic Syndrome|Acute Myeloid Leukemia |
2013-06-01 |
2022-04-06 |
Primary Endpoints|Treatments |
|
| The TOPAZ Study | P2 |
Unknown status |
Acute Myeloid Leukemia |
2013-06-01 |
2019-03-19 |
Treatments |
|
| HOVON 103 AML Tosedostat | P2 |
Active, not recruiting |
Acute Myeloid Leukemia|Anemia, Refractory, with Excess of Blasts |
2013-02-16 |
2025-05-06 |
Treatments |
|
| OPAL study | P2 |
Completed |
Acute Myeloid Leukemia |
2011-05-11 |
2022-03-13 |
Treatments |
|
| OPAL | P2 |
Completed |
Acute Myeloid Leukemia |
2011-03-01 |
2019-03-18 |
Treatments |
|
| 2005-004955-36 | P2 |
Completed |
Myelodysplastic Syndrome|Leukemia|Multiple Myeloma |
2008-07-14 |
2022-03-12 |
Treatments |
|
| CHR-2797-005 | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
2008-02-01 |
2019-03-21 |
Treatments |
|
| CHR-2797-002 | P2 |
Completed |
Multiple Myeloma|Acute Myeloid Leukemia|Myelodysplastic Syndrome|Preleukemia|Leukemia, Plasma Cell |
2007-12-01 |
2019-03-18 |
||
| LI-1 | P3 |
Unknown status |
Acute Myeloid Leukemia|Myelodysplastic Syndrome |
2019-05-04 |
2025-06-23 |
Treatments |
|
| AMLM20 | P3 |
Terminated |
Myelodysplastic Syndrome|Leukemia |
2017-02-23 |
2024-08-29 |
Treatments |